FactCheck determined Health Secretary Robert F. Kennedy Jr. overstated Food and Drug Administration drug approval rates using misleading historical comparisons.
Kennedy contrasted current review speeds with past decades without adjusting for changes in trial design, emergency pathways and disease areas.
His remarks coincided with debate over a new expedited program that compresses timelines for selected therapies.
Regulatory scholars said selective baselines can make modest process shifts appear dramatic.
The FDA has defended its frameworks as maintaining safety benchmarks even when calendar times shrink for breakthrough candidates.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.factcheck.org/